Bausch Health Companies Inc. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases
Bausch Health Companies Inc. (BHC) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases of $2.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Notes › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation › Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases, (Sales), Issuances, (Settlements)
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases · last filed 2026-07-30
- Bausch Health Companies Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, purchases for the quarter ending 2025-12-31 was $3.00M, a 96.59% decline year-over-year.
- Bausch Health Companies Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, purchases for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- Bausch Health Companies Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, purchases for the quarter ending 2024-12-31 was $88.00M.
- Bausch Health Companies Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, purchases for the quarter ending 2024-09-30 was $1.00M, a 97.06% decline year-over-year.
- Bausch Health Companies Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, purchases for fiscal 2025 was $3.00M, a 96.63% decline from fiscal 2024.
- Bausch Health Companies Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, purchases for fiscal 2024 was $89.00M, a 134.21% increase from fiscal 2023.
- Bausch Health Companies Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, purchases for fiscal 2023 was $38.00M.
- Bausch Health Companies Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, purchases for fiscal 2022 was $0.00.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.00M 10-Q · filed 2026-07-30 | |||
| 2025-12-31 | $3.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $3.00M derived: sum of 2 quarters · filed 2026-02-19 | $3.00M 10-K · filed 2026-02-19 | |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $0.00 10-Q · filed 2025-10-30 | ||
| 2025-06-30 | $0.00 10-Q · filed 2026-07-30 | |||
| 2024-12-31 | $88.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $89.00M derived: sum of 2 quarters · filed 2026-02-19 | $89.00M derived: sum of 3 quarters · filed 2026-02-19 | $89.00M 10-K · filed 2026-02-19 |
| 2024-09-30 | $1.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $1.00M derived: sum of 2 quarters · filed 2025-10-30 | $1.00M 10-Q · filed 2025-10-30 | $0.00 derived: sum of 4 quarters · filed 2025-10-30 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $0.00 10-Q · filed 2024-08-01 | -$1.00M derived: sum of 3 quarters · filed 2025-02-20 | $33.00M derived: sum of 4 quarters · filed 2025-02-20 |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-02 | -$1.00M derived: sum of 2 quarters · filed 2025-02-20 | $33.00M derived: sum of 3 quarters · filed 2025-02-20 | $33.00M derived: sum of 4 quarters · filed 2025-02-20 |
| 2023-12-31 | -$1.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-20 | $33.00M derived: sum of 2 quarters · filed 2025-02-20 | $33.00M derived: sum of 3 quarters · filed 2025-02-20 | $38.00M 10-K · filed 2025-02-20 |
| 2023-09-30 | $34.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $34.00M derived: sum of 2 quarters · filed 2024-10-31 | $39.00M 10-Q · filed 2024-10-31 | $39.00M derived: sum of 4 quarters · filed 2024-10-31 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $5.00M 10-Q · filed 2024-08-01 | $5.00M derived: sum of 3 quarters · filed 2024-08-01 | $5.00M derived: sum of 4 quarters · filed 2024-08-01 |
| 2023-03-31 | $5.00M 10-Q · filed 2024-05-02 | $5.00M derived: sum of 2 quarters · filed 2024-05-02 | $5.00M derived: sum of 3 quarters · filed 2024-05-02 | $5.00M derived: sum of 4 quarters · filed 2024-05-02 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $0.00 derived: sum of 2 quarters · filed 2024-02-22 | $0.00 derived: sum of 3 quarters · filed 2024-02-22 | $0.00 10-K · filed 2024-02-22 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $0.00 derived: sum of 2 quarters · filed 2023-11-02 | $0.00 10-Q · filed 2023-11-02 | |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $0.00 10-Q · filed 2023-08-03 | ||
| 2022-03-31 | $0.00 10-Q · filed 2023-05-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 |